256 related articles for article (PubMed ID: 29271043)
1. Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom.
Davies O; Szladovits B; Polton G; Garden OA; Leo C; Lara-Garcia A
Vet Comp Oncol; 2018 Jun; 16(2):276-287. PubMed ID: 29271043
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol.
Curran K; Thamm DH
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():147-55. PubMed ID: 26279153
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol.
Wolf-Ringwall A; Lopez L; Elmslie R; Fowler B; Lori J; Sfiligoi G; Skope A; Arnold E; Hughes KL; Thamm DH; Ehrhart EJ; Avery AC; Lana SE
Vet Comp Oncol; 2020 Sep; 18(3):342-352. PubMed ID: 31682319
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma.
Childress MO; Ramos-Vara JA; Ruple A
Vet Comp Oncol; 2018 Mar; 16(1):E159-E168. PubMed ID: 29152834
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma.
Treggiari E; Elliott JW; Baines SJ; Blackwood L
Vet Comp Oncol; 2018 Jun; 16(2):194-201. PubMed ID: 28766920
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cytoreductive efficacy of vincristine, cyclophosphamide, and Doxorubicin in dogs with lymphoma by measuring the number of neoplastic lymphoid cells with real-time polymerase chain reaction.
Sato M; Yamazaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
J Vet Intern Med; 2011; 25(2):285-91. PubMed ID: 21314729
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma.
Al-Nadaf S; Rebhun RB; Curran KM; Venable RO; Skorupski KA; Willcox JL; Burton JH
BMC Vet Res; 2018 Nov; 14(1):356. PubMed ID: 30458771
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience.
Smallwood K; Tanis JB; Grant IA; Blackwood L; Killick DR; Amores-Fuster I; Elliott J; Mas A; Harper A; Marrington M; Finotello R
Vet Comp Oncol; 2019 Jun; 17(2):165-173. PubMed ID: 30666777
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood cell ratios as prognostic factors in canine diffuse large B-cell lymphoma treated with CHOP protocol.
Henriques J; Felisberto R; Constantino-Casas F; Cabeçadas J; Dobson J
Vet Comp Oncol; 2021 Jun; 19(2):242-252. PubMed ID: 33247533
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of baseline absolute lymphocyte concentration and neutrophil/lymphocyte ratio in dogs with newly diagnosed multi-centric lymphoma.
Mutz M; Boudreaux B; Kearney M; Stroda K; Gaunt S; Shiomitsu K
Vet Comp Oncol; 2015 Dec; 13(4):337-47. PubMed ID: 23786518
[TBL] [Abstract][Full Text] [Related]
12. Intermittent single-agent doxorubicin for the treatment of canine B-cell lymphoma.
Higginbotham ML; McCaw DL; Roush JK; Nietfeld JC; Wilkerson MJ; Reeds K; Burr D
J Am Anim Hosp Assoc; 2013; 49(6):357-62. PubMed ID: 24051255
[TBL] [Abstract][Full Text] [Related]
13. CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.
Rebhun RB; Kent MS; Borrofka SA; Frazier S; Skorupski K; Rodriguez CO
Vet Comp Oncol; 2011 Mar; 9(1):38-44. PubMed ID: 21303452
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
Wang SL; Lee JJ; Liao AT
Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clinical response and prognostic factors in canine multicentric lymphoma treated with first rescue therapy.
Blaxill JE; Bennett PF
Vet Comp Oncol; 2024 Jun; 22(2):265-277. PubMed ID: 38646859
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma.
Lautscham EM; Kessler M; Ernst T; Willimzig L; Neiger R
Vet Rec; 2017 Mar; 180(12):303. PubMed ID: 28100766
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017).
Elliott J; Baines S
Aust Vet J; 2019 Sep; 97(9):308-315. PubMed ID: 31328256
[TBL] [Abstract][Full Text] [Related]
19. Response-based modification of CHOP chemotherapy for canine B-cell lymphoma.
Benjamin SE; Sorenmo KU; Krick EL; Salah P; Walsh KA; Weinstein NM; Keuler NS; Avery AC; Atherton MJ; Lenz JA
Vet Comp Oncol; 2021 Sep; 19(3):541-550. PubMed ID: 33729654
[TBL] [Abstract][Full Text] [Related]
20. Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma?
Hahn KA; Richardson RC; Teclaw RF; Cline JM; Carlton WW; DeNicola DB; Bonney PL
J Vet Intern Med; 1992; 6(1):3-10. PubMed ID: 1548624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
